JP2024527001A - ループスの治療 - Google Patents

ループスの治療 Download PDF

Info

Publication number
JP2024527001A
JP2024527001A JP2024504491A JP2024504491A JP2024527001A JP 2024527001 A JP2024527001 A JP 2024527001A JP 2024504491 A JP2024504491 A JP 2024504491A JP 2024504491 A JP2024504491 A JP 2024504491A JP 2024527001 A JP2024527001 A JP 2024527001A
Authority
JP
Japan
Prior art keywords
anifrolumab
dose
subject
sle
ifnar1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527001A5 (cg-RX-API-DMAC7.html
Inventor
リンドホルム,カタリーナ
トゥマラ,ラジェンドラ
マオ,エマニュエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2024527001A publication Critical patent/JP2024527001A/ja
Publication of JP2024527001A5 publication Critical patent/JP2024527001A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2024504491A 2021-07-27 2022-07-26 ループスの治療 Pending JP2024527001A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163225974P 2021-07-27 2021-07-27
US63/225,974 2021-07-27
US202163254663P 2021-10-12 2021-10-12
US63/254,663 2021-10-12
PCT/EP2022/070860 WO2023006700A1 (en) 2021-07-27 2022-07-26 Treatment of lupus

Publications (2)

Publication Number Publication Date
JP2024527001A true JP2024527001A (ja) 2024-07-19
JP2024527001A5 JP2024527001A5 (cg-RX-API-DMAC7.html) 2025-08-05

Family

ID=83059135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504491A Pending JP2024527001A (ja) 2021-07-27 2022-07-26 ループスの治療

Country Status (9)

Country Link
US (1) US20250326850A1 (cg-RX-API-DMAC7.html)
EP (1) EP4377349A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024527001A (cg-RX-API-DMAC7.html)
KR (1) KR20240038773A (cg-RX-API-DMAC7.html)
AU (1) AU2022317215A1 (cg-RX-API-DMAC7.html)
CA (1) CA3226744A1 (cg-RX-API-DMAC7.html)
IL (1) IL310241A (cg-RX-API-DMAC7.html)
TW (1) TW202340245A (cg-RX-API-DMAC7.html)
WO (1) WO2023006700A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD1120170S1 (en) * 2024-03-28 2026-03-24 Karsten Manufacturing Corporation Golf club head

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150158949A1 (en) * 2012-06-13 2015-06-11 Medlmmune, Llc Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
ES2643237T3 (es) 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
SMT201700063T1 (it) 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
SI3769781T1 (sl) 2015-08-19 2023-06-30 Astrazeneca Ab Stabilna formulacija proti-IFNAR1
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150158949A1 (en) * 2012-06-13 2015-06-11 Medlmmune, Llc Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ACR MEETING ABSTRACTS, JPN6026028742, 2019, pages 2563, ISSN: 0005908862 *
ANNALS OF THE RHEUMATIC DISEASES, vol. 75, JPN6026028748, 2016, pages 293, ISSN: 0005908861 *
ANNALS OF THE RHEUMATIC DISEASES, vol. 80, JPN6026028746, 19 May 2021 (2021-05-19), pages 590 - 591, ISSN: 0005908859 *
ARTHRITIS & RHEUMATOLOGY, vol. 69, no. 2, JPN6026028743, 2017, pages 376 - 386, ISSN: 0005908863 *
MODERN RHEUMATOLOGY, vol. 31, no. 1, JPN6026028744, 2 January 2021 (2021-01-02), pages 1 - 12, ISSN: 0005908857 *
THE LANCET RHEUMATOLOGY, vol. Vol.3, February 2021, JPN6026028745, 20 November 2020 (2020-11-20), pages 101 - 110, ISSN: 0005908858 *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 382, no. 3, JPN6026028747, 16 January 2020 (2020-01-16), pages 211 - 221, ISSN: 0005908860 *

Also Published As

Publication number Publication date
TW202340245A (zh) 2023-10-16
AU2022317215A1 (en) 2024-02-29
WO2023006700A1 (en) 2023-02-02
IL310241A (en) 2024-03-01
KR20240038773A (ko) 2024-03-25
CA3226744A1 (en) 2023-02-02
EP4377349A1 (en) 2024-06-05
US20250326850A1 (en) 2025-10-23

Similar Documents

Publication Publication Date Title
EP4114465B1 (en) Anti-ifnar1 dosing regime for subcutaneous injection
AU2021356122B2 (en) Treatment of flares in lupus
US20250002589A1 (en) Treatment of cutaneous lupus erythematous
US20250326850A1 (en) Treatment of lupus
US20250002591A1 (en) Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythermatosus patients
CN117677638A (zh) 狼疮的治疗
EA052183B1 (ru) Лечение кожной красной волчанки
JP2025533978A (ja) ループスの治療
HK40087032B (en) Anti-ifnar1 dosing regime for subcutaneous injection
HK40087032A (en) Anti-ifnar1 dosing regime for subcutaneous injection
JP2024527001A5 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260714